Owain Donnelly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Owain Donnelly has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Alejandro Garcia Leon
Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Dublin, Ireland
2 shared publications- Amy Dykes
Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
2 shared publications Benson Jacob
Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
2 shared publicationsBrian Li
School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
2 shared publications- Chiara De Santi
School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
2 shared publications - David Neary
Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
2 shared publications
Latest Publications
- Open Access
- 17 July 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (12) , e484-e491
A Retrospective Study of the Management of Pediatric Cutaneous Leishmaniasis in a Non-endemic Setting
Introduction: Cutaneous leishmaniasis (CL), caused by protozoa of the genus Leishmania , is a neglected tropical disease. Limited evidence exists to inform the management of CL in children and adolescents, and experience in non-endemic settings varies significantly. We report case data and treatment outcomes for 17 children and young people diagnosed with CL and treated at a specialist tropical medicine center in the United Kingdom. Methods: The electronic patient records of 17 patients less than 18 years old with CL who were treated at University College London Hospitals between October 2015 and June 2025 were accessed to gather data including demographics (age, sex, country of origin), likely country of CL acquisition, causative species of Leishmania , treatment given and treatment outcome. Causative agents included L. donovani complex (n = 6), L. major (n = 5), L. tropica (n = 4), L. Viannia subgenus (n = 1) and a Leishmania species where subgenus or species could not be determined (n = 1). Results: Conservative management (2/17), oral miltefosine (9/17), intralesional meglumine antimoniate (3/17) and intravenous liposomal amphotericin B (LAMB; 3/17) were used as first-line treatment approaches in this cohort. Two patients were lost to follow-up, but complete resolution was observed in 14 of the remaining 15 patients by day 180 post-treatment initiation, with 1 child’s lesion taking longer than this to fully re-epithelialize. Adverse effects of treatment were observed in 6/17 (35%) patients and were mild or moderate. Conclusions: Our data show that miltefosine, intralesional meglumine antimoniate and LAMB are effective, safe and well-tolerated treatments for children with CL in non-endemic settings. Management of children and young adults with CL may present additional complexity compared to adults, such as difficulty obtaining biopsy samples, lack of evidence for drug dosing regimens and tolerability of painful injections, which need to be administered repeatedly. Individualized treatment decisions should be made in conjunction with children, young people and their families, and a multidisciplinary approach is recommended.
- 17 July 2026
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (12) , e484-e491
Open AccessA Retrospective Study of the Management of Pediatric Cutaneous Leishmaniasis in a Non-endemic Setting
Introduction: Cutaneous leishmaniasis (CL), caused by protozoa of the genus Leishmania , is a neglected tropical disease. Limited evidence exists to inform the management of CL in children and adolescents, and experience in non-endemic settings varies significantly. We report case data and treatment outcomes for 17 children and young people diagnosed with CL and treated at a specialist tropical medicine center in the United Kingdom. Methods: The electronic patient records of 17 patients less than 18 years old with CL who were treated at University College London Hospitals between October 2015 and June 2025 were accessed to gather data including demographics (age, sex, country of origin), likely country of CL acquisition, causative species of Leishmania , treatment given and treatment outcome. Causative agents included L. donovani complex (n = 6), L. major (n = 5), L. tropica (n = 4), L. Viannia subgenus (n = 1) and a Leishmania species where subgenus or species could not be determined (n = 1). Results: Conservative management (2/17), oral miltefosine (9/17), intralesional meglumine antimoniate (3/17) and intravenous liposomal amphotericin B (LAMB; 3/17) were used as first-line treatment approaches in this cohort. Two patients were lost to follow-up, but complete resolution was observed in 14 of the remaining 15 patients by day 180 post-treatment initiation, with 1 child’s lesion taking longer than this to fully re-epithelialize. Adverse effects of treatment were observed in 6/17 (35%) patients and were mild or moderate. Conclusions: Our data show that miltefosine, intralesional meglumine antimoniate and LAMB are effective, safe and well-tolerated treatments for children with CL in non-endemic settings. Management of children and young adults with CL may present additional complexity compared to adults, such as difficulty obtaining biopsy samples, lack of evidence for drug dosing regimens and tolerability of painful injections, which need to be administered repeatedly. Individualized treatment decisions should be made in conjunction with children, young people and their families, and a multidisciplinary approach is recommended.
- Open Access
- 6 September 2025
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 67, 102903
Leishmaniasis in the United Kingdom: Experience of a national multidisciplinary team meeting in a non-endemic setting
- 6 September 2025
- Published by Elsevier in Travel Medicine and Infectious Disease
- Vol. 67, 102903
Open AccessLeishmaniasis in the United Kingdom: Experience of a national multidisciplinary team meeting in a non-endemic setting
- Open Access
- 15 October 2021
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 4, 85
Concordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing
Introduction : Saliva represents a less invasive alternative to nasopharyngeal swab (NPS) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. SalivaDirect is a nucleic acid extraction-free method for detecting SARS-CoV2 in saliva specimens. Studies evaluating the concordance of gold standard NPS and newly developed SalivaDirect protocols are limited. The aim of our study was to assess SalivaDirect as an alternative method for COVID-19 testing. Methods : Matching NPS and saliva samples were analysed from a cohort of symptomatic (n=127) and asymptomatic (n=181) participants recruited from hospital and university settings, respectively. RNA was extracted from NPS while saliva samples were subjected to the SalivaDirect protocol before RT-qPCR analysis. The presence of SARS-Cov-2 was assessed using RdRp and N1 gene targets in NPS and saliva, respectively. Results : Overall we observed 94.3% sensitivity (95% CI 87.2-97.5%), and 95.9% specificity (95% CI 92.4-97.8%) in saliva when compared to matching NPS samples. Analysis of concordance demonstrated 95.5% accuracy overall for the saliva test relative to NPS, and a very high level of agreement (κ coefficient = 0.889, 95% CI 0.833–0.946) between the two sets of specimens. Fourteen of 308 samples were discordant, all from symptomatic patients. Ct values were >30 in 13/14 and >35 in 6/14 samples. No significant difference was found in the Ct values of matching NPS and saliva sample ( p =0.860). A highly significant correlation (r = 0.475, p <0.0001) was also found between the Ct values of the concordant positive saliva and NPS specimens. Conclusions : Use of saliva processed according to the SalivaDirect protocol represents a valid method to detect SARS-CoV-2. Accurate and less invasive saliva screening is an attractive alternative to current testing methods based on NPS and would afford greater capacity to test asymptomatic populations especially in the context of frequent testing.
- 15 October 2021
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 4, 85
Open AccessConcordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing
Introduction : Saliva represents a less invasive alternative to nasopharyngeal swab (NPS) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. SalivaDirect is a nucleic acid extraction-free method for detecting SARS-CoV2 in saliva specimens. Studies evaluating the concordance of gold standard NPS and newly developed SalivaDirect protocols are limited. The aim of our study was to assess SalivaDirect as an alternative method for COVID-19 testing. Methods : Matching NPS and saliva samples were analysed from a cohort of symptomatic (n=127) and asymptomatic (n=181) participants recruited from hospital and university settings, respectively. RNA was extracted from NPS while saliva samples were subjected to the SalivaDirect protocol before RT-qPCR analysis. The presence of SARS-Cov-2 was assessed using RdRp and N1 gene targets in NPS and saliva, respectively. Results : Overall we observed 94.3% sensitivity (95% CI 87.2-97.5%), and 95.9% specificity (95% CI 92.4-97.8%) in saliva when compared to matching NPS samples. Analysis of concordance demonstrated 95.5% accuracy overall for the saliva test relative to NPS, and a very high level of agreement (κ coefficient = 0.889, 95% CI 0.833–0.946) between the two sets of specimens. Fourteen of 308 samples were discordant, all from symptomatic patients. Ct values were >30 in 13/14 and >35 in 6/14 samples. No significant difference was found in the Ct values of matching NPS and saliva sample ( p =0.860). A highly significant correlation (r = 0.475, p <0.0001) was also found between the Ct values of the concordant positive saliva and NPS specimens. Conclusions : Use of saliva processed according to the SalivaDirect protocol represents a valid method to detect SARS-CoV-2. Accurate and less invasive saliva screening is an attractive alternative to current testing methods based on NPS and would afford greater capacity to test asymptomatic populations especially in the context of frequent testing.
- Open Access
- 30 July 2021
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 4, 85
Concordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing
Introduction : Saliva represents a less invasive alternative to nasopharyngeal swab (NPS) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. SalivaDirect is a nucleic acid extraction-free method for detecting SARS-CoV2 in saliva specimens. Studies evaluating the concordance of gold standard NPS and newly developed SalivaDirect protocols are limited. The aim of our study was to to assess SalivaDirect as an alternative method for COVID-19 testing. Methods : Matching NPS and saliva samples were analysed from a cohort of symptomatic (n=127) and asymptomatic (n=181) participants recruited from hospital and university settings, respectively. RNA was extracted from NPS while saliva samples were subjected to the SalivaDirect protocol before RT-qPCR analysis. The presence of SARS-Cov-2 was assessed using RdRP and N1 gene targets in NPS and saliva, respectively. Results : Overall we observed 94.3% sensitivity (95% CI 87.2-97.5%), and 95.9% specificity (95% CI 92.4-97.8%) in saliva when compared to matching NPS samples. Analysis of concordance demonstrated 95.5% accuracy overall for the saliva test relative to NPS, and a very high level of agreement (κ coefficient = 0.889, 95% CI 0.833–0.946) between the two sets of specimens. Fourteen of 308 samples were discordant, all from symptomatic patients. Ct values were >30 in 13/14 and >35 in 6/14 samples. No significant difference was found in the Ct values of matching NPS and saliva sample ( p =0.860). A highly significant correlation (r = 0.475, p <0.0001) was also found between the Ct values of the concordant positive saliva and NPS specimens. Conclusions : Use of saliva processed according to the SalivaDirect protocol represents a valid method to detect SARS-CoV-2. Accurate and less invasive saliva screening is an attractive alternative to current testing methods based on NPS and would afford greater capacity to test asymptomatic populations especially in the context of frequent testing.
- 30 July 2021
- Published by F1000 Research Ltd in HRB Open Research
- Vol. 4, 85
Open AccessConcordance between PCR-based extraction-free saliva and nasopharyngeal swabs for SARS-CoV-2 testing
Introduction : Saliva represents a less invasive alternative to nasopharyngeal swab (NPS) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. SalivaDirect is a nucleic acid extraction-free method for detecting SARS-CoV2 in saliva specimens. Studies evaluating the concordance of gold standard NPS and newly developed SalivaDirect protocols are limited. The aim of our study was to to assess SalivaDirect as an alternative method for COVID-19 testing. Methods : Matching NPS and saliva samples were analysed from a cohort of symptomatic (n=127) and asymptomatic (n=181) participants recruited from hospital and university settings, respectively. RNA was extracted from NPS while saliva samples were subjected to the SalivaDirect protocol before RT-qPCR analysis. The presence of SARS-Cov-2 was assessed using RdRP and N1 gene targets in NPS and saliva, respectively. Results : Overall we observed 94.3% sensitivity (95% CI 87.2-97.5%), and 95.9% specificity (95% CI 92.4-97.8%) in saliva when compared to matching NPS samples. Analysis of concordance demonstrated 95.5% accuracy overall for the saliva test relative to NPS, and a very high level of agreement (κ coefficient = 0.889, 95% CI 0.833–0.946) between the two sets of specimens. Fourteen of 308 samples were discordant, all from symptomatic patients. Ct values were >30 in 13/14 and >35 in 6/14 samples. No significant difference was found in the Ct values of matching NPS and saliva sample ( p =0.860). A highly significant correlation (r = 0.475, p <0.0001) was also found between the Ct values of the concordant positive saliva and NPS specimens. Conclusions : Use of saliva processed according to the SalivaDirect protocol represents a valid method to detect SARS-CoV-2. Accurate and less invasive saliva screening is an attractive alternative to current testing methods based on NPS and would afford greater capacity to test asymptomatic populations especially in the context of frequent testing.